Patents by Inventor Hemanta Baruah

Hemanta Baruah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TARGETING FLT3 AND USE THEREOF
    Publication number: 20240132598
    Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting FLT3 on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.
    Type: Application
    Filed: October 13, 2020
    Publication date: April 25, 2024
    Inventors: Hemanta Baruah, Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Zong Sean Juo, Thomas J. McQuade
  • PROTEINS BINDING NKG2D, CD16 AND FLT3
    Publication number: 20240117054
    Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD 16, and FLT3 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of autoimmune disease or cancer.
    Type: Application
    Filed: October 14, 2020
    Publication date: April 11, 2024
    Inventors: Hemanta Baruah, Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Zong Sean Juo, Thomas J. McQuade, Daniel Fallon, William Haney, Steven O'Neil, Ronnie Wei
  • CD38 MODULATING ANTIBODY
    Publication number: 20240092928
    Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: September 1, 2023
    Publication date: March 21, 2024
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
  • CD38 modulating antibody
    Patent number: 11780930
    Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: October 10, 2023
    Assignee: BLACK BELT THERAPEUTICS LIMITED
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
  • Antibodies Targeting CLEC12A and Use Thereof
    Publication number: 20230220084
    Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting CLEC12A on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.
    Type: Application
    Filed: May 5, 2021
    Publication date: July 13, 2023
    Inventors: Hemanta Baruah, Gregory P. Chang, Ann F. Cheung, Asya Grinberg
  • CD38 MODULATING ANTIBODY AGENTS
    Publication number: 20230103584
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: June 8, 2018
    Publication date: April 6, 2023
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
  • CD38 MODULATING ANTIBODY
    Publication number: 20230089373
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: November 30, 2022
    Publication date: March 23, 2023
    Inventors: Anne GOUBIER, Josephine SALIMU, Kevin MOULDER, Beatriz GOYENECHEA CORZO, Simone FILOSTO, Pascal MERCHIERS, Nina EISSLER, Hemanta BARUAH, Bianka PRINZ
  • CD38 modulating antibody
    Patent number: 11542338
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: January 3, 2023
    Assignee: BLACK BELT THERAPEUTICS LIMITED
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
  • Anti-OX40 antibody and use thereof
    Patent number: 11498972
    Abstract: The present invention relates to an antibody and antibody fragment that specifically binds to OX40 and to a composition comprising said antibody or antibody fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or antibody fragment thereof and a host cell comprising the same, and to a related use thereof. In addition, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: November 15, 2022
    Assignee: Innovent Biologics (Suzhou) Co., Ltd.
    Inventors: Andy Tsun, Hemanta Baruah, Xiaolin Liu, Cheng Chen, Junjian Liu, Bingliang Chen, Weifeng Huang
  • CD38 ANTIBODY
    Publication number: 20220135697
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: January 18, 2022
    Publication date: May 5, 2022
    Inventors: Anne GOUBIER, Josephine SALIMU, Kevin MOULDER, Beatriz GOYENECHEA CORZO, Simone FILOSTO, Pascal MERCHIERS, Nina EISSLER, Hemanta BARUAH, Bianka PRINZ
  • PROTEINS BINDING NKG2D, CD16 AND CLEC12A
    Publication number: 20220119534
    Abstract: Described herein are multispecific binding proteins that bind NKG2D receptor, CD16, and CLEC12A, pharmaceutical compositions comprising the multispecific binding proteins, and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: May 5, 2021
    Publication date: April 21, 2022
    Inventors: Hemanta Baruah, Gregory P. Chang, Ann F. Cheung, Daniel Fallon, Asya Grinberg, Zong Sean Juo, Christopher Ryan Morgan
  • CD38 antibody
    Patent number: 11236173
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: February 1, 2022
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
  • ANTIBODY VARIABLE DOMAINS TARGETING DLL3, AND USE THEREOF
    Publication number: 20220025037
    Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting DLL3 (Delta-like 3) on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.
    Type: Application
    Filed: April 3, 2019
    Publication date: January 27, 2022
    Inventors: Hemanta Baruah, Ann F. Cheung, Daniel Fallon, Asya Grinberg, William Haney, Steven O'Neil
  • CD38 MODULATING ANTIBODY AGENTS
    Publication number: 20210277138
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: June 8, 2018
    Publication date: September 9, 2021
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenchea Corzo, Hemanta Baruah, Bianka Prinz
  • PD-1 antibodies
    Patent number: 10913801
    Abstract: The present invention relates to antibodies that bind human programmed cell death 1 (PD-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: February 9, 2021
    Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Hemanta Baruah, Cheng Chen, Xiaolin Liu, Andy Tsun, De-Chao Michael Yu
  • CD38 ANTIBODY
    Publication number: 20200362050
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: August 16, 2018
    Publication date: November 19, 2020
    Inventors: Anne GOUBIER, Josephine SALIMU, Kevin MOULDER, Beatriz GOYENECHEA CORZO, Simone FILOSTO, Pascal MERCHIERS, Nina EISSLER, Hemanta BARUAH, Bianka PRINZ
  • CD38 MODULATING ANTIBODY
    Publication number: 20200362049
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: August 16, 2018
    Publication date: November 19, 2020
    Inventors: Anne GOUBIER, Josephine SALIMU, Kevin MOULDER, Beatriz GOYENECHEA CORZO, Simone FILOSTO, Pascal MERCHIERS, Nina EISSLER, Hemanta BARUAH, Bianka PRINZ
  • MULTISPECIFIC ANTIBODY ANALOGS COMPRISING A COMMON LIGHT CHAIN, AND METHODS OF THEIR PREPARATION AND USE
    Publication number: 20200223939
    Abstract: Multispecific antibody analogs that co-engage at least two different antigens or epitopes (also referred to targets, used interchangeably throughout), said analogs comprising a common light chain, are provided, as well as methods for their production and use.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 16, 2020
    Inventors: Hemanta Baruah, Robert Mabry
  • CD38 MODULATING ANTIBODY
    Publication number: 20200190209
    Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: June 8, 2018
    Publication date: June 18, 2020
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
  • ANTI-OX40 ANTIBODY AND USE THEREOF
    Publication number: 20200140562
    Abstract: The present invention relates to a novel antibody and antibody fragment that specifically binds to OX40 and to a composition comprising said antibody or antibody fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or antibody fragment thereof and a host cell comprising the same, and to a related use thereof. In addition, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.
    Type: Application
    Filed: March 23, 2018
    Publication date: May 7, 2020
    Inventors: Andy Tsun, Hemanta Baruah, Xiaolin Liu, Cheng Chen, Junjian Liu, Bingliang Chen, Weifeng Huang